Core Viewpoint - Vivos Therapeutics, Inc. (VVOS) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years, highlighting the importance of earnings revisions in stock valuation [1][4]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, driven by institutional investors who adjust their valuations based on these estimates [4][5]. Recent Developments for Vivos Therapeutics - For the fiscal year ending December 2024, Vivos Therapeutics is expected to earn -$1.79 per share, representing an 86.3% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Vivos Therapeutics has increased by 42.8%, reflecting a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Vivos Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy